The biopharmaceutical industry likely will feel the impact of the Trump Administration’s weekend purge of hundreds of US Food and Drug Administration probationary employees in many ways over the coming weeks and months.
US FDA Staff Cuts: Biopharma Industry Braces For Impact, But First Wants Clarity On Losses
Stakeholders are waiting for the dust to settle to better understand who was laid off as part of the Trump Administration's cuts at the FDA, the reductions' impact on applications currently under review and broader drug development efforts.
